+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07293351

ROSETTA RCC-208 Evaluating Pumitamig Alone or With Other Agents in Advanced Renal Cell Carcinoma Treatment

Led by Bristol-Myers Squibb · Updated on 2026-10-23

474

Participants Needed

95

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of Pumitamig alone or combined with other drugs in people with advanced Renal Cell Carcinoma RCC, a type of kidney cancer. This study is in phases 1 and 2 and is designed to better understand how these treatments work in patients with both clear cell and non-clear cell RCC, focusing on those with locally advanced or metastatic disease. Participants will receive Pumitamig alone or in combination with other agents such as Ipilimumab, Cabozantinib, or Casdatifan. The study includes multiple experimental treatment groups, where specific doses are given on specified days. The treatments are administered in a randomized, open-label manner, and the study aims to observe responses over time. The trial includes up to approximately two years of treatment monitoring, with some outcome measures extending up to four years from randomization. Throughout the study, participants will be assessed for side effects, treatment response, and disease progression using established criteria. Researchers will monitor adverse events, dose-limiting toxicities, and serious side effects. Evaluations include measuring tumor response by imaging and clinical assessments. The study also tracks progression-free survival and duration of response. Follow-up continues for up to two years after treatment completion to understand long-term outcomes and safety.

CONDITIONS

Brief Title

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here